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Abstract 
In 2012, seized capsules containing white powder were analyzed to show the presence of 
unknown steroid-related compounds.  Subsequent GC-MS and NMR investigations identified 
a mixture of 3- and 3- isomers of the novel compound; 3-chloro-17-methyl-5-
androstan-17-ol.  Synthesis of authentic reference materials followed by comparison of 
NMR, GC-MS and GC-MS-MS data confirmed the finding of a new “designer” steroid.  
Furthermore, in vitro androgen bioassays showed potent activity highlighting the potential for 
doping using this steroid.  Owing to the potential toxicity of the halogenated steroid, in vitro 
metabolic investigations of 3-chloro-17-methyl-5-androstan-17-ol using equine and 
human S9 microsomal liver fractions were performed.  For equine, GC-MS-MS analysis 
identified the diagnostic 3-chloro-17-methyl-5-androstane-1617-diol metabolite.  For 
human, the 17-methyl-5-androstane-317-diol metabolite was found.  Results from these 
studies were used to verify the ability of GC-MS-MS precursor-ion scanning techniques to 
support untargeted detection strategies for designer steroids in anti-doping analyses. 
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Anti-doping, Designer steroids, Androgen bioassay, Steroid metabolism, Gas 
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Introduction 
The use of androgens with the aim of increasing performance presents a serious threat to the 
integrity of animal and human sports, and they are therefore prohibited for use by the 
International Federation of Horseracing Authorities
[1]
 and World Anti-Doping Agency
[2]
, 
respectively.  Until recently, most abused androgens were marketed synthetic analogs that 
were approved for therapeutic use for treatment of recognized medical disorders.  However, 
since the turn of the 21
st
 century the illicit production and distribution of novel, never-
marketed synthetic androgens selected to evade doping control has been uncovered.  Such 
“designer” steroids feature chemical modifications and may not be detected by existing 
doping control methods, which rely on knowledge of the chemical structure and 
metabolism.
[3-6]
  These novel agents are developed using knowledge of structure-activity 
relationships in the patent literature derived from the thousands of compounds (including 
androgens) investigated during post-war decades that comprised the “Golden Age” of steroid 
pharmacology.
[7] 
 
The first such designer androgen was norbolethone (13,17-diethyl-17-hydroxygon-4-en-
3-one) identified by Catlin et al.
[8]
 in 2002.  This androgen, synthesized in 1966 and studied 
clinically but never marketed for anabolic effects, had never been identified in athletes’ 
urine.
[8]
  In 2004, the same group discovered tetrahydrogestrinone (13,17-diethyl-17-
hydroxygon-4,9,11-trien-3-one; THG) following analysis of a spent syringe provided 
anonymously to the United States Anti-Doping Agency (USADA) that had allegedly 
contained an anabolic steroid undetectable by doping control tests.
[9]
  THG was produced by a 
facile one-step chemical reduction of gestrinone, a marketed progestin.  THG was proven by 
Death et al.
[10]
 to be a highly potent androgen using an in vitro androgen bioassay expressing 
the human androgen receptor linked to a chemical read-out.  This provided crucial evidence 
for the first successful prosecution of THG use in the BALCO scandal.  In the absence of 
toxicological information for THG, Lévesque et al.
[11]
 applied in vitro studies using human 
hepatocytes to propose C16- and C18-hydroxylated metabolites as glucuronide conjugates. 
 
Subsequent discovery of desoxymethyltestosterone (17-methyl-5-androst-2-en-17-ol; 
DMT or Madol)
[12]
 soon after prompted anti-doping laboratories to commit additional 
resources to the identification of designer androgens,
[13-20]
 with investigations complementing 
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conventional in vivo administration studies with in vitro methodologies.  Ethical and safety 
considerations precluded conventional in vivo clinical studies as had been used for marketed 
synthetic androgens.  The advantages and limitations of in vitro methods specific to equine 
metabolic studies of anabolic steroids have been described by Wong et al.
[21]
 
 
Concerning the present study, in 2012 red and black capsules that contained white powder 
were seized by Queensland authorities in Australia and analyzed by forensic chemists to show 
the presence of unknown steroid-related compounds.  We describe herein the identification, 
synthesis, in vitro androgenic bioactivity, in vitro metabolic studies using both equine and 
human liver S9 fraction, and Gas Chromatography-tandem Mass Spectrometry (GC-MS-MS) 
methods for detection in routine anti-doping analysis of 3-chloro-17-methyl-5-androstan-
17-ol.  The workflow presented is proposed as a suitable template for the study of designer 
steroids in racehorses. 
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Experimental 
Commercial reference materials, chemicals and reagents 
Epiandrosterone (3-hydroxy-5-androstan-17-one) and androsterone (3-hydroxy-5-
androstan-17-one) were purchased from Steraloids, Inc. (Newport, RI, USA).  d3-Testosterone 
was purchased from the National Measurement Institute (Sydney, NSW, Australia).  
Chemicals and solvents used at the Australian National University for synthesis were 
purchased from Sigma-Aldrich (Castle Hill, Australia) and used as supplied unless otherwise 
specified.  All general laboratory chemicals and reagents used at the Australian Racing 
Forensic Laboratory for analysis were of HPLC grade and were purchased from Thermo 
Fisher Scientific (Fair Lawn, NJ, USA).  Merck petroleum benzine boiling range 40-60 °C 
(hexanes) was used as supplied.  Dry diethyl ether and tetrahydrofuran (THF) were obtained 
by distillation from sodium wire as required.  Triphenylphosphine was recrystallized from 
methanol and dried under vacuum before use.  meta-Chloroperoxybenzoic acid was 
recrystallized from dichloromethane and dried under vacuum before use.  Reactions were 
monitored by analytical thin layer chromatography (TLC) using Merck Silica gel 60 TLC 
plates using the specified solvents and were visualized with a solution of concentrated sulfuric 
acid in methanol (5% v/v) with heating as required.  Column chromatography was performed 
using Merck Silica gel 60 (230-400 mesh) using the specified solvents.  N-methyl-N-
(trimethylsilyl)trifluoroacetamide was purchased from UCT (Bristol, PA, USA).   Ammonium 
iodide was obtained from BDH (Poole, UK).  Water was obtained using a Millipore filtration 
system (Bedford, MA, USA). 
 
NMR spectroscopy 
Analysis of seized material at Griffith University 
Spectra were acquired on a Varian 400MHz Unity INOVA spectrometer in d6-DMSO/CDCl3 
solvent at 298K.  
1
H and 
13
C{
1
H} NMR chemical shifts are referenced to d6-DMSO solvent 
residuals, taken as 2.49 ppm and 39.9 ppm respectively.  2D gradient filtered COSY, 
heteronuclear single quantum correlation (gHSQC) and heteronuclear multiple bond 
correlations (gHMBC) were acquired using the standard sequences implicit in the VNMRJ 
2.1b software package.  NOE difference spectra were acquired using the cyclenoe sequence 
implicit in the VNMRJ software package, with internal data subtraction.  Control frequencies 
were set 1-2 ppm from saturating frequencies where possible.  Saturation times were set to 4s, 
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with mix and tau values both set to 100 ms.  256-800 transients were acquired and 0.5 Hz line 
broadening functions acquired to the difference spectrum prior to Fourier Transform. 
 
Analysis of synthesized 3/-chloro-17a-methyl-5a-androstan-17-ol at the Australian 
National University 
1
H and 
13
C NMR spectra were recorded using either Varian 400 MHz, Bruker Avance 400 
MHz or Bruker Avance 600 MHz spectrometers at 298 K using deuterated chloroform 
solvent. Data are reported in parts per million (ppm), referenced to residual chloroform or 
deuterated chloroform solvent respectively (
1
H: 7.26 ppm, 
13
C: 77.16 ppm) and multiplicity is 
assigned as follows: brs = broad singlet, s = singlet, d = doublet, t = triplet, m = multiplet. 
Coupling constants J are reported in Hertz. 
 
GC-MS analysis 
Analysis of seized material at Queensland Forensic and Scientific Services 
Analysis was performed on an Agilent 5890 GC-MS equipped with Agilent J&W HP5-MS 
and HP-1 (30m x 0.25mm x 0.25m) columns.  Helium was used as a carrier gas at a constant 
flow rate of 1.8mL/min.  Injection volumes of 1 L were used in a pulse-splitless mode with 
an injector temperature of 280 C.  The oven temperature commenced at 65 C with a hold 
time of 1 min, followed by a 40C/min ramp rate to 300 C and a final hold time of 13 min.  
Mass spectra were collected over a m/z 35-550 scan range with an ionization energy of 70 eV. 
 
Analysis of synthesized 3/-chloro-17a-methyl-5a-androstan-17-ol at the Australian 
Racing Forensic Laboratory 
Stock standards of 200 g/mL for each isomer were made by dissolving 1 mg of reference 
material in 5 mL methanol.  Aliquots (20 L) were dried under N2 at 50 °C before 
trimethylsilyl (TMS) derivatization using N-methyl-N-
(trimethylsilyl)trifluoroacetamide/ammonium iodide/dithioerythritol (1000:2:4 v/w/w, 50 L) 
at 80 °C for 60 minutes. 
 
An Agilent 6890 GC coupled to a 5973 MS (Palo Alto, CA, USA) was used.  The GC column 
was a Restek Rtx-5Sil-MS (15 m x 0.25 mm x 0.25 m) with helium as carrier gas.  Sample 
injections (2 L) were made in splitless mode with an injector temperature of 260 °C.  The 
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column was initially held 180 °C for 0.2 min, then was increased at 5 °C/min to 235 °C, 15 
°C/min to 265 °C, then finally 25 °C/min to 300 °C and held for 10 min.  Head pressure was 
programmed to maintain a constant flow rate of 1.2 mL/min.  The MS transfer line was set at 
300 °C and the ion source was operated in EI+ mode with an ionization energy of 70 eV.  
Data was acquired in scan mode (m/z 50 to 650) using Agilent ChemStation
®
 software. 
 
Purification of seized material 
The combined contents of three seized capsules (1.04 g) were extracted in 10 mL of methanol 
with sonication.  The methanol extract was filtered and evaporated to dryness under nitrogen.  
The residue was taken up in 1 mL of the eluant solution (10% ethyl acetate/n-hexane) and 
loaded on to a silica gel (Kieselgel 60, 0.2-0.5mm, Merck) column of approximate 
dimensions 10 cm x 2 cm (id).  Fraction collection commenced after the band had progressed 
five centimeters.  A mixture of compounds (3) and (6) was recovered (approximately 6 mg) 
from fractions 29-35, which were evaporated under nitrogen. 
 
Synthesis of reference materials 
Synthesis of 17-methyl-5-androstane-317-diol and 17-methyl-5-androstane-317-
diol used in this study was described previously by McKinney et al.
[22]
  Melting points were 
determined using a SRS Optimelt MPA 100 melting point apparatus and are uncorrected.  
Optical rotations were determined using a Perkin-Elmer 241MC polarimeter (sodium D line 
at 25 °C).  Low-resolution mass spectrometry (LRMS) and high-resolution mass spectrometry 
(HRMS) were performed using positive electron ionization (+EI) on a Micromass VG 
Autospec mass spectrometer at the Australian National University Mass spectrometry facility.  
IR spectra were recorded using a Bruker Alpha FT-IR Spectrometer and peaks are reported in 
wavenumbers (cm
-1
) and described as follows: br = broad, s = strong, m = medium, w = 
weak, with assignment of major bands. 
 
Synthesis of 3-chloro-17-methyl-5-androstan-17-ol reference materials 
The target 3-chloro-17α-methyl-5α-androstan-17β-ols had not been previously reported in the 
literature.  They could be accessed by methylation of the corresponding known 3-chloro-5α-
androstan-17-ones
[23]
 which in turn could be synthesized from the 3-hydroxy-5α-androstan-
17-ones by chlorination with inversion of configuration at the reacting center.
[24]
  To this end 
epiandrosterone (1) underwent chlorination to afford 3α-chloro-5α-androstan-17-one (2)[23] in 
79% yield (Figure 1).  Methylation of this compound provided 3α-chloro-17α-methyl-5α-
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androstan-17β-ol (3) in 56% yield.  The identity and stereochemistry of this compound was 
confirmed by X-ray crystallography (Supporting Information, Figure S10).
[25]
  In a similar 
manner, androsterone (4) underwent chlorination to afford 3β-chloro-5α-androstan-17-one 
(5)
[23]
 in 27% yield followed by methylation to give 3β-chloro-17α-methyl-5α-androstan-17β-
ol (6) in 32% yield.  Detailed synthesis conditions and results are provided in Supporting 
Information. 
 
Synthesis of 16-hydroxylated reference materials 
The synthesis of the 16-hydroxylated reference materials was completed as outlined in 
Figure 2.  Formation of the enol acetate (7) from ketone (2) followed by a sequence involving 
epoxidation, rearrangement and acetylation afforded the acetoxy-ketone (8).  Subjecting this 
material to Grignard reaction with methylmagnesium bromide gave a separable mixture of 
3-chloro-17-methyl-5-androstane-16,17-diol (9) and 3-chloro-17-methyl-5-
androstane-16,17-diol (10) in a 6.5:1 ratio.  Detailed synthesis conditions and results are 
provided in Supporting Information. 
 
In vitro androgen bioassays 
The in vitro yeast and mammalian (HuH7 and HEK293) cell androgen bioassays have been 
previously described by Akram et al.
[27]
  For the yeast cell androgen  bioassay, early to mid-
log phase yeast cells were sub-cultured into 24-well plates (500 µL/well) and androgen 
receptor (AR) expression activated with 1 µM CuSO4.  Cells were then treated with steroids 
(5 µL/well) over a concentration range to generate a sigmoidal dose curve used to calculate 
the EC50 of the steroid response.  Treatment continued overnight at 30 °C with vigorous 
orbital shaking (300 rpm).  Yeast cell growth was stalled by ice treatment for 30 min.  The 
optical density (600 nm) was measured then cells were lysed and assayed for β-galactosidase 
activity using a standard assay.  For the mammalian cell androgen bioassay, HuH7 and 
HEK293 cells were seeded in 96-well plates (1x105 cells/mL) and allowed to recover 
overnight in phenol red-free DMEM supplemented with 10% charcoal-stripped FCS, L-
glutamine and 5.5 µg/mL puromycin.  Cells were then treated with steroids over a 
concentration range to generate a sigmoidal dose response curve.  Cells were heated for 35 
min at 65 °C to deactivate endogenous alkaline phosphatase before SEAP activity was 
measured using a commercially available assay (Clontech Laboratories, CA, USA).  The EC50 
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for both the yeast and mammalian cell-based assays was determined from a sigmoidal curve 
fit using GraphPad. 
 
In-vitro metabolism studies 
A solution containing -NAD (1.5 mM), magnesium chloride (4.5 mM), glucose-6-phosphate 
(7.5 mM), glucose-6-phosphate dehydrogenase (1 unit), equine or human liver S9 fraction (1 
mg protein) and 3-chloro-17-methyl-5-androstan-17-ol (250 g) in sodium phosphate 
buffer (50 mM, pH 7.4, 1 mL) and methanol (2 L) was incubated with shaking in an open 
tube at 37 °C for 3 h.  The reaction was quenched with acetonitrile (1 mL) and centrifuged 
(2000 rpm, 5 min).  The resulting supernatant solution was decanted and extracted with ethyl 
acetate (2 x 1 mL) and the organic layer was dried under a stream of nitrogen.  Residues were 
analyzed by GC-MS-MS after formation of 1.) TMS derivatives as outlined above and 2.) 
acetonide-TMS derivatives to investigate C16-C17 stereochemistry using a modified version of 
the procedure described by Houghton and Dumasia,
[28]
  specifically the reaction of acetone 
(0.5 mL) and trifluoroacetic acid (50 L) at 55 °C for 60 min, drying under N2 at 60 °C, 
followed by TMS-ether formation.  The final extracts were dried under nitrogen at 60 °C 
before being reconstituted in n-dodecane (50 L) for GC-MS-MS analysis.  Control 
experiments were performed in parallel in the absence of (a) cofactor regeneration (-NAD, 
magnesium chloride, glucose-6-phosphate and glucose-6-phosphate dehydrogenase), (b) 
equine or human liver S9 fraction and (c) steroid (3-chloro-17-methyl-5-androstan-17-
ol). 
 
Isolation of steroids from urine 
Urine (3 mL) aliquots were fortified with d3T (1 g/mL, 30 L) as surrogate before 
adjustment to pH 6 (±0.2) with the addition of 10% HCl.  Enzyme hydrolysis was performed 
using -glucuronidase K12 from E.coli (20 L) overnight at 37 °C.  Urinary steroids were 
isolated by solid phase extraction using ABS Elut NEXUS
®
 extraction columns (60 mg, 3 cc, 
Agilent Technologies, Lake Forest, CA, USA) that were conditioned with methanol (3 mL) 
and water (3 mL) before loading with sample, washed with 0.1 M NaOH (1 mL) and water (3 
mL) before elution with methanol (3 mL).  The eluates were evaporated to dryness under 
nitrogen at 60 °C.  Equine urine samples were then subjected to chemical hydrolysis with 
methanolic HCl (1M, 0.5 mL) at 60 °C for 15 minutes. After cooling to room temperature the 
reaction was quenched with sodium hydroxide (2M, 3 mL) before extraction with di-
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isopropylether (4 mL). The tubes were centrifuged at 2000 rpm before the organic supernatant 
was transferred to a clean test tube and evaporated to dryness under nitrogen at 60 °C.  Equine 
and human steroid extracts were derivatized to form TMS ethers as described above prior to 
the final extracts being dried under nitrogen at 60 °C and reconstituted in n-dodecane (50 L) 
for GC-MS-MS analysis. 
 
GC-MS-MS analysis 
An Agilent 7000B GC-MS-MS (Palo Alto, CA, USA) was used.  The GC column was an 
Agilent J&W HP5-MS (30 m x 0.25 mm x 0.25 m) with helium as carrier gas.  Sample 
injections (2 L) were made in pulsed-splitless mode with an injector temperature of 260 °C.  
The column was initially held 180 °C for 0.2 min, then was increased at 5 °C/min to 235 °C, 
15 °C/min to 265 °C, then finally 25 °C/min to 300 °C and held for 10 min.  Head pressure 
was programmed to maintain a constant flow rate of 1.2 mL/min.  The MS transfer line was 
set at 300°C and the ion source was operated in EI+ mode with an ionization energy of 70 eV.  
Nitrogen was used for the collision gas at 1.5 mL/min. Instrument control and processing was 
performed using Agilent MassHunter
®
 software.  Mass spectra were acquired in full scan (m/z 
50-650), product ion scan, multiple reaction monitoring (MRM) and precursor ion scan 
modes using optimized parameters outlined herein.  Qualitative confirmation of identity was 
performed by comparison between sample and reference standard according to Association of 
Official Racing Chemists criteria.
[29]
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Results 
GC-MS 
Analysis of seized material at Queensland Forensic and Scientific Services 
A methanol extract of the seized capsules showed two major peaks by GCMS at 7.58 and 
7.61 min (Figure 3).  Both peaks provided similar mass spectra with a molecular ion at m/z 
324, however slight differences in relative ion ratios were observed.  The mass difference of 
34 amu and 3:1 chlorine isotope pattern displayed by these peaks in comparison to an earlier 
peak at 6.90 min suggested a putative chloromethylandrostanol structure.  Based on the 
chlorine position of previously encountered steroids, such as clostebol and 4-
chlorodehydromethyltestosterone (oral turinabol), a 4-chlorinated structure was initially 
theorized, but chlorine substitution was later shown by NMR to be at the C3-position.  
Samples of the synthesized compounds (3) and (6) were analyzed in parallel with the seized 
material as TMS derivatives (Figure 4).  The molecular ion at m/z 396 and the presence of m/z 
130 and 143 supported the formation of mono-O-TMS derivatives and a 17-methyl-17-
hydroxy structure,
[30-32]
 respectively. 
 
Analysis of synthesized 3-chloro-17a-methyl-5a-androstan-17-ol by the Australian Racing 
Forensic Laboratory 
The full scan spectrum revealed m/z 73 (TMS, 20%), 130 (15%), 143 (100%), 264 (3%), 291 
([M-CH3-OTMS]
+
, 5%), 306 ([M-OTMS]
+
, 3%), 381 ([M-CH3]
+
, 8%) and 396 ([M]
+∙
, 1%).  
The presence of chlorine was supported by an accompanying [M+2]
+
 ion at one-third 
abundance for m/z 291, 306, 381 and 396.  The diagnostic fragment ions at m/z 130 and 143 
result from the well characterized D-ring cleavage described for TMS derivatives of C17-
methyl/C17-hydroxylated steroids.
[30-32]
  Comparison to the spectra in Figure 4 provided 
additional agreement between the seized material and synthesized steroid. 
 
NMR 
Analysis of seized material at Griffith University 
The purified fraction of the seized material was analyzed using 
1
H and 
13
C NMR 
spectroscopy.  The data were consistent with a 2.5:1 mixture of 3α-chloro-17α-methyl-5α-
androstan-17β-ol (3) and 3β-chloro-17α-methyl-5α-androstan-17β-ol (6). 
 12 
 
The 400 MHz 
1
H NMR spectrum of the mixture (Supporting Information, Figure S1) showed 
a high degree of complexity, with significant overlapping of resonances, due to both the 
relatively poor dispersion of the aliphatic resonances at the comparatively low field strength 
and the presence of the two species in the sample.  The structural elucidation of the 
components of the mixture was therefore based on a number of specific diagnostic 
observations.  Expansions of the 400 MHz 
1
H NMR spectrum of the mixture focusing on the 
resonances assigned to the protons attached to the carbon bearing the chloro substituent are 
provided in Figure 5.  Qualitative splitting diagrams for the two resonances are illustrated.  
Both resonances exhibit four doublet couplings; the major component showing four similar 
couplings (~4-5Hz), the minor component showing two pairs of similar couplings (~4-5Hz 
and ~12Hz).  This suggested substitution at position C2 or C3 (and not C1 or C4), as the 
carbons will be flanked by two methylene units given the observed couplings. NOE, 
13
C 
chemical shift and gHMBC data obtained for the mixture, confirmed attachment of the chloro 
substituents to C3 in both compounds. 
 
The 
13
C{
1
H}  NMR spectrum of the seized material is provided in Supporting Information, 
Figure S2.  2D gHSQC and gHMBC analysis of the sample facilitated assignment of the 
relevant 
13
C chemical shifts (Supporting Information, Figures S3 and S5).  Confirmation of 
the attachment of the chloro substituent to the C3 carbons of the two compounds was obtained 
via a series of selective NOE experiments (Supporting Information, Figure S6).  Selective 
saturation of the H3 proton of (6; 3.82 ppm) resulted in enhancement of the mutually axial H1 
and H5 protons.  Partial saturation of the broad resonance of the axial methylene proton of the 
major compound (3; 1.84 ppm) resulted in the expected NOE enhancement of the protons of 
the C19 methyl group, with no observable enhancement of the H5 proton resonance, 
confirming the methylene’s location at C2 and thus the attachment of the chloro substituent to 
C3 of the A-ring. 
 
The chemical shifts of the protons and the carbons of the C- and D-rings of both compounds 
showed close correspondence, indicating similar substitution in those rings.  The 
stereochemistry of the C17 substituents was established by selective irradiation of the C17 
hydroxyl protons (Supporting Information, Figure S4).  Strong NOE enhancement of the 
resonances of both the C18 and C20 methyl groups, as well as enhancement of the adjacent β 
C16 and equatorial C12 methylene proton resonances, was observed.  Enhancement of both 
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methyl substituents locates the hydroxyl substituents on the top faces of the molecules (i.e. in 
the β position). 
 
In vitro androgen bioassays 
Results from Yeast, HEK293 and HuH7 androgen receptor bioassays are summarized in 
Table 1.  In the yeast androgen bioassay, compared with testosterone (T) and 
dihydrotestosterone (DHT) over the range of 10
-4 
M to 10
-10 
M, both isomers displayed 
androgenic bioactivity with the 3-chloro-17-methyl-5-androstan-17-ol having a similar 
potency to T but less than DHT whereas the 3-chloro-17-methyl-5-androstan-17-ol 
isomer had low relative potency.  No cellular toxicity was observed for either isomer. 
 
HEK293 cells, a human embryonic kidney cell line, express limited levels of steroid 
metabolizing enzymes.  Both isomers displayed androgenic bioactivity with the 3-chloro-
17-methyl-5-androstan-17-ol comparable to T but an order of magnitude more potent 
than the 3-chloro-17-methyl-5-androstan-17-ol isomer.  Neither isomer showed any 
cellular toxicity. 
 
HuH7, human liver cell line, cells express steroid metabolizing enzymes at higher levels than 
HEK293 cells.  Both 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-
5-androstan-17-ol displayed androgenic bioactivity in similar relative proportions to their 
bioactivity in the HEK293 cell line. 
 
In-vitro metabolic analysis 
A predictive MS strategy, based on results from previous studies investigating equine 
metabolism of 17-methyltestosterone and mestanolone,[22,33] and human endogenous 
steroids,
[34]
 was applied to identify candidate products from incubation with equine and 
human S9 fractions that required further investigation by GC-MS-MS.  Precursor ions 
selected for TMS derivatives for mono-, bis- and tris-hydroxylated steroids considered to be 
potentially formed from 3-chloro-17-methyl-5-androstan-17-ol starting material are 
provided in Table 2. 
 
Equine S9 fraction 
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Product ion experiments targeting m/z 484 identified a response at Rt=15.46 min that 
indicated the 3-chloro substituent of the parent steroid was conserved.  Control experiments 
showed no presence of this response in the absence of co-factor, equine S9 liver microsomes 
or parent steroid.  Putative identification of 3-chloro-17-methyl-5-androstane-16,17-
diol was based on 1.) the presence of m/z 231 reported by McKinney et al.
[22]
 and Schoene et 
al.
[31]
 to be diagnostic of C16-hydroxylated metabolites of 17-methyltestosterone, and 2.) 
unsuccessful formation of the cis-acetonide derivative supporting 16-stereochemistry.[28]  
The identity of 3-chloro-17-methyl-5-androstane-16,17-diol was confirmed by 
comparison of the equine S9 fraction to the synthesized reference material (Figure 6).  The 
stereochemistry of C16-hydroxyl and C17-hydroxyl/methyl substituents was verified by 
performing acetonide-TMS derivative experiments on synthesized 3-chloro-17-methyl-5-
androstane-16,17-diol and 3-chloro-17-methyl-5-androstane-16,17-diol reference 
materials, with the latter used as a control standard to demonstrate the efficiency of cis-
acetonide derivative formation. 
 
Human S9 fraction 
Product ion experiments targeting m/z 450 identified a response at Rt=13.92 min.  Control 
experiments showed no presence of this response in the absence of co-factor, human S9 liver 
microsomes or parent steroid.  The identity of 17-methyl-5-androstane-3,17-diol was 
confirmed by comparison of the human S9 fraction to a certified reference material and 
verification of C3 stereochemistry by comparison to 17-methyl-5-androstane-3,17-diol 
(Figure 7).  The equine metabolite; 3-chloro-17-methyl-5-androstane-16,17-diol was 
not detected. 
 
Translation to routine doping control 
Product ion scan experiments were used to optimize collision energies for MRM transitions 
corresponding to 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-
androstane-16,17-diol that could be included with 17-methyl-5-androstane-3,17-diol 
into routine anabolic steroid screening (Table 3).  The limit of detection (LOD) for each 
steroid was determined from triplicate analysis of three authentic blank equine and human 
urine samples together with steroid spikes (n=3) of the same urine samples at concentrations 
of 0.1, 0.2, 0.5, 1, 2, 5 and 10 ng/mL. 
 
 15 
Extraction recovery was evaluated by comparison of 1 and 10 ng/mL pre- and post-extraction 
spikes in each of the three equine and human blank urine samples.  Relatively poor results 
were obtained for the three target analytes in equine urine; 3-chloro-17-methyl-5-
androstan-17-ol (10-11%), 3-chloro-17-methyl-5-androstane-16,17-diol (30-34%) 
and 17-methyl-5-androstane-3,17-diol (21-24%).  Recoveries observed from spiking of 
human urine samples were far superior; 3-chloro-17-methyl-5-androstan-17-ol (51-
56%), 3-chloro-17-methyl-5-androstane-16,17-diol (82-85%) and 17-methyl-5-
androstane-3,17-diol (77-81%), indicating acid hydrolysis used in the equine method to be 
the likely cause. 
 
The estimated LOD of 0.5 ng/mL for the most sensitive transitions of the target analytes 
provides effective routine screening capability in equine urine.  Example chromatograms for 
3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstane-
16,17-diol are provided by Figures 8 and 9, respectively.  The limit of confirmation, 
however, is determined by the LOD for the least sensitive of a minimum three MRM 
transitions required to satisfy AORC criteria.
[29]
  This was estimated at 5 ng/mL for 3-
chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstane-16,17-
diol in equine urine. 
 
GC-MS-MS precursor ion strategies 
The work of Thevis and Schӓnzer[32] has been used to develop “untargeted” steroid analysis 
methods using precursor ion scanning of fragments arising from diagnostic dissociation 
mechanisms.  In addition to the metabolic and translational foci of the current study, the 
opportunity was taken to evaluate the application of this detection mode to designer steroids 
in horses.  A strategy based on monitoring m/z 143, 218 and 231 was first applied to the 
analysis of in vitro extracts obtained from equine S9 incubation.  This afforded precursor ion 
scans that displayed high S/N (>10) for parent (i.e. unreacted) 3-chloro-17-methyl-5-
androstan-17-ol (m/z 143) and 3-chloro-17-methyl-5-androstane-16,17-diol (m/z 218 
and m/z 231).  These results supported the potential for precursor ion scanning to identify 
novel products from in vitro studies. 
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In equine urine, however, matrix effects were observed to significantly reduce S/N for the 
target compounds (Table 4) surveyed between 2 ng/mL and 10 ng/mL.  The best results were 
observed for 17-methyl-5-androstane-3,17-diol by monitoring m/z 143.  Parent 3-
chloro-17-methyl-5-androstan-17-ol using the same ion was poor, even at 10 ng/mL, 
thereby requiring further work to evaluate m/z 130 as a suitable alternative.  Equine 
metabolite 3-chloro-17-methyl-5-androstane-16,17-diol displayed reasonable 
precursor ion (m/z 218) sensitivity at concentrations greater than 5 ng/mL (Figure 10).  
Inclusion of m/z 169 into a precursor ion scan strategy will be important for identifying 
unknown steroids containing a C17-ketone moiety.
[35]
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Discussion 
 
The identification of designer steroids by anti-doping laboratories has to date relied 
on investigative testing of bulk materials seized and submitted by law enforcement 
agencies or acquired via ad-hoc procurement.  The former identified 3/-chloro-
17-methyl-5-androstan-17-ol using underivatized and TMS full-scan GC-MS, 1H 
NMR and 
13
C NMR techniques.  These findings were confirmed following 
underivatized and TMS full-scan GC-MS comparison to synthesized reference 
materials of both isomers. 
 
Investigations of designer steroids should include an assessment of androgenic 
bioactivity to assess the likelihood of misuse and to therefore prioritize the investment 
required to develop detection methods.  Using a panel of yeast and mammalian host 
cell in vitro androgen bioassays providing a complementary rapid and sensitive 
appraisal of androgen activity, it was shown that both 3-chloro-17-methyl-5-
androstan-17-ol and 3-chloro-17-methyl-5-androstan-17-ol are androgens, 
with the former having higher intrinsic androgenic activity.  In addition, both are 
likely to be relatively resistant to either activating or inactivating metabolism in the 
body after ingestion.  To explore metabolism effects, both isomers were assessed for 
bioactivity in the HEK293 and HuH7 androgen bioassays to show expression of 
steroid metabolizing enzymes, while retaining similar relative potencies and therefore 
indicating little impact of mammalian cell metabolism.  In considering the likely 
potency of these isomers in vivo, other relevant factors including species-specific 
metabolism (as illustrated by the diagnostic metabolite profiles in horse and man) and 
circulating half-life, which is largely determined by its binding to sex-hormone 
binding globulin, need to be assessed but are undefined at present. 
 
Having identified the novel steroid(s) and assessed the potency to support a target 
likely for misuse, in vitro and/or in vivo metabolic studies can be performed.  Owing 
to the halogenation of the target steroid in this study, only the former was employed 
to mitigate any risk to animal and human welfare.  This was conducted using the 
microsomal S9 fractions for equine and human metabolism of 3-chloro-17-methyl-
5-androstan-17-ol and identified the major metabolites; 3-chloro-17-methyl-5-
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androstane-16,17-diol and 17-methyl-5-androstane-3,17-diol, respectively.  
Conservation of the chlorine substituent highlights the diagnostic potential of the 
equine metabolite.  The discrete equine and human in vitro metabolism will require 
further investigation in vivo should the toxicity of 3-chloro-17-methyl-5-
androstan-17-ol prove to be negligible and therefore safe for administration.  Indeed, 
limitations need to be considered in assuming correlation of in vitro and in vivo 
experiments.
[36]
  For example, additional hydroxylation may be expected in vivo, with 
the potential to provide longer detection periods.  Conceivably, 3-chloro-17-
methyl-5-androstan-17-ol could be metabolized to 17-methyl-5-androstan-
3,16,17-triol.  Furthermore, the excretion of parent steroid in vivo cannot be 
discounted and so has been included in the routine screening method. 
 
While there is merit to the adoption of precursor ion strategies for complementary 
untargeted detection of “designer” steroids, validation in matrix is imperative to 
assess performance.  The results of this study have highlighted the limitation in 
sensitivity with precursor ion scanning.  Greater sensitivity may be achieved in 
complex matrices such as equine urine using more conventional selected ion 
monitoring (SIM) strategies where MS cycle time allows.  Further to hardware 
considerations, the use of differential and in silico software applications will likely 
provide anti-doping laboratories with the capability for de novo identification of 
“designer” steroids in the future. 
 
The importance of high quality organic synthesis should not be underestimated.  First, 
for timely and unambiguous identification of the parent steroid, and second for 
responsive translation into routine screening of metabolites.
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Conclusion 
In this study, 
1
H NMR and 
13
C NMR experiments provided unequivocal proof of 
identity and assisted MS interpretation for 3-chloro-17-methyl-5-androstan-
17-ol in seized material.  To the author’s knowledge, the discovery of a C3-
chlorinated steroid presumed to be intended for doping purposes has not been 
previously reported.  Synthesis of 3-chloro-17-methyl-5-androstan-17-ol 
enabled an assessment of doping potential using in vitro androgen bioassays.  With a 
high potency recorded, GC-MS-MS studies of in vitro metabolic extracts produced 
from incubation of the synthesized steroid with equine S9 microsomal liver fractions 
provided evidence of a putative diagnostic equine metabolite (3-chloro-17-methyl-
5-androstane-16,17-diol) that was subsequently synthesized to confirm its 
identity.  A previously reported metabolite (17-methyl-5-androstane-3,17-diol) 
of methyltestosterone and mestanolone was confirmed from in vitro experiments with 
human S9 microsomal liver fractions.  These compounds were incorporated into the 
routine anabolic steroid screening procedure for equine urine samples. 
 
This research provides an example for anti-doping laboratories to respond to the 
threat of designer steroids in animal or human sports.  The greatest challenge can be 
to first obtain intelligence as to what illegitimate products may be available and 
therefore misused.  The internet can be useful for this purpose, however, resource 
limitations preclude comprehensive reviews by the doping control community at any 
given time.  To alleviate this problem, collaboration with forensic drug laboratories 
performing evidentiary analysis for law-enforcement agencies can provide 
intelligence of relevant designer drug targets for investigation.
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Table 1: Relative AR potency of 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstan-17-ol 
Cell type T 
EC50 (nM) 
 
Relative 
potency
#
 
DHT 
EC50 (nM) 
 
Relative 
potency
#
 
3 
EC50 (nM) 
 
Relative 
potency
#
 
3
EC50 (nM) 
 
Relative 
potency
#
 
Yeast 4.812E
-09
 1 1.825E
-09
 2.64 3.278E
-09
 1.47 1.283E
-07
 0.04 
HEK293 9.274E
-10
 1 6.128E
-11
 15.13 1.07E
-09
 0.87 4.566E
-08
 0.02 
HuH7 5.78E
-08
 1 1.141E
-08
 5.07 5.59E
-08
 1.03 6.697E
-07
 0.09 
# to testosterone (T)
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Table 2: Predicted precursor ions of TMS steroids from in vitro S9 experiments 
Precursor ion 
(m/z) 
Steroid 
360 17-methyl-5-androst-2-en-17-ol (Madol) 
396 3-chloro-17-methyl-5-androstan-17-ol 
448 17-methyl-5-androstan-17-ol-3-one (mestanolone) 
450 17-methyl-5-androstane-3,17-diol 
484 hydroxylated 3-chloro-17-methyl-5-androstan-17-ol 
536 hydroxylated mestanolone 
538 hydroxylated 17-methyl-5-androstane-3,17-diol 
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Table 3: Optimized MRM parameters for detection of TMS derivatives by GC-MS-MS 
Steroid 
Retention time 
(min) 
Relative 
retention 
MRM 
transition(s) 
Collision energy 
(V) 
LOD 
(ng/mL) 
D3-testosterone (INSTD) 14.25 1.000 435 > 420* 10  
3-chloro-17-methyl-5-androstan-17-ol 14.25 1.000 381 > 291* 
396 > 143 
396 > 381 
15 
15 
15 
0.5 
5.0 
2.0 
3-chloro-17-methyl-5-androstan-17-ol 14.35 1.007 
^ ^  
3-chloro-17-methyl-5-androstane-16,17-diol 15.46 1.085 484 > 218 
 484 > 231* 
484 > 469 
15 
15 
15 
5.0 
0.5 
5.0 
17-methyl-5-androstane-3,17-diol 13.93 0.978 435 > 345* 
450 > 143 
450 > 435 
15 
15 
15 
0.5 
2.0 
1.0 
17-methyl-5-androstane-3,17-diol 14.56 1.022 
^ ^  
 
* Transition used for quantification 
^ As above 
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Table 4: Detection capability using GC-MS-MS in precursor ion scan mode. 
Steroid m/z 
Concentration 
(ng/mL) 
Comment 
17-methyl-5-androstane-3,17-diol 143 2 
5 
10 
S/N < 3:1 
4
th
 most intense peak in chromatogram 
2
nd
 most intense peak in chromatogram 
3-chloro-17-methyl-5-androstan-17-ol 143 2 
5 
10 
Unable to identify due to matrix interference at RT 
^ 
^ 
3-chloro-17-methyl-5-androstane-16,17-diol 
 
 
 
^ As above 
218 2 
5 
10 
S/N < 3:1 
8
th
 most intense peak in chromatogram 
6
th
 most intense peak in chromatogram 
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List of figure legends 
 
Figure 1: Synthesis of reference materials used in the investigation of 3-chloro-
17-methyl-5-androstan-17-ol. 
 
Figure 2: Synthesis of 16-hydroxylated reference materials. 
 
Figure 3: Total Ion Chromatogram of methanol extract on HP5-MS column (top), full 
scan MS of peak at 7.58 min (middle) and full scan MS of peak at 7.61 min (bottom). 
 
Figure 4: Full scan MS of seized compound identified as (3; top) and (6; bottom) as 
TMS derivatives. 
 
Figure 5: (a) Resolution enhanced expansion of the region of the 
1
H NMR spectrum 
(400MHz, 298K, d6-DMSO/CDCl3) of the seized material, centered at δ 4.47ppm.  
All four observed doublet splittings are small (~4-5Hz) and consistent with the values 
expected for 
3
Jeq,ax and 
3
Jeq,eq couplings, placing the H3 proton in the equatorial 
position. (b) An expansion of the region of the same spectrum centered at δ 3.82ppm.  
The two larger (~12Hz) trans-diaxial doublet splittings are highlighted (bold). 
 
Figure 6: Full scan GC-MS spectrum and structure of bis-TMS 3-chloro-17-
methyl-5-androstane-16,17-diol equine metabolite. 
 
Figure 7: Product ion chromatograms (m/z 450) of human S9 fraction (top), bis-TMS 
17-methyl-5-androstane-3,17-diol (middle) and 17-methyl-5-androstane-
3,17-diol (bottom). 
 
Figure 8: MRM (381>291) for mono-TMS 3-chloro-17-methyl-5-androstan-17-
ol in blank equine urine (top), 1 ng/mL equine urine spike (middle) and synthesized 
reference material (bottom). 
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Figure 9: MRM (484>231) for bis-TMS 3-chloro-17-methyl-5-androstane-
16,17-diol in blank equine urine (top), 1 ng/mL equine urine spike (middle) and 
synthesized reference material (bottom). 
 
Figure 10: Precursor ion scan (m/z 218) for bis-TMS 3-chloro-17-methyl-5-
androstane-16,17-diol in blank equine urine (top), 10 ng/mL equine urine spike 
(middle) and synthesized reference material (bottom). 
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Figure 1: Synthesis of reference materials used in the investigation of 3-chloro-17-methyl-5-androstan-17-ol. 
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Figure 2: Synthesis of 16-hydroxylated reference materials. 
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Figure 3: Total Ion Chromatogram of methanol extract on HP5-MS column (top), full 
scan MS of peak at 7.58 min (middle) and full scan MS of peak at 7.61 min (bottom). 
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Figure 4: Full scan MS of seized compounds identified as (3; top) and (6; bottom) as 
TMS derivatives. 
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Figure 5: (a) Resolution enhanced expansion of the region of the 
1
H NMR spectrum 
(400MHz, 298K, d6-DMSO/CDCl3) of the seized material, centered at δ 4.47ppm.  
All four observed doublet splittings are small (~4-5Hz) and consistent with the values 
expected for 
3
Jeq,ax and 
3
Jeq,eq couplings, placing the H3 proton in the equatorial 
position. (b) An expansion of the region of the same spectrum centered at δ 3.82ppm.  
The two larger (~12Hz) trans-diaxial doublet splittings are highlighted (bold). 
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Figure 6: Full scan GC-MS spectrum and structure of bis-TMS 3-chloro-17-
methyl-5-androstane-16,17-diol equine metabolite. 
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Figure 7: Product ion chromatograms (m/z 450) of human S9 fraction (top), bis-TMS 
17-methyl-5-androstane-3,17-diol (middle) and 17-methyl-5-androstane-
3,17-diol (bottom). 
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Figure 8: MRM (381>291) for mono-TMS 3-chloro-17-methyl-5-androstan-17-
ol in blank equine urine (top), 1 ng/mL equine urine spike (middle) and synthesized 
reference material (bottom). 
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Figure 9: MRM (484>231) for bis-TMS 3-chloro-17-methyl-5-androstane-
16,17-diol in blank equine urine (top), 1 ng/mL equine urine spike (middle) and 
synthesized reference material (bottom). 
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Figure 10: Precursor ion scan (m/z 218) for bis-TMS 3-chloro-17-methyl-5-
androstane-16,17-diol in blank equine urine (top), 10 ng/mL equine urine spike 
(middle) and synthesized reference material (bottom). 
 
 
